Australasian Leukaemia & Lymphoma Group

MENLO PARK, Calif., June 20, 2024 /PRNewswire/ -- Escend Pharmaceuticals, Inc., a privately held oncology company, announced today a poster presentation with initial data from the Australasian Leukaemia and Lymphoma Group's (ALLG) investigator-initiated Phase I/II platform study (MYDAS-T MDS05 domain 1) evaluating ES-3000 alone and in combination with ASTX727 at European Hematology Association (EHS) in Madrid, Spain. The poster is entitled, 'Combining oral Wnt/β catenin/inflammasome pathway inhibitor, a bis-benzylisoquinoline alkaloid (ES-3000) with oral decitabine/cedazuridine (ASTX727)* as a treatment strategy for myelodysplasia'. The primary objectives of the initial phase of the trial are to assess the safety profile of ES-3000 and determine the recommended phase 2 dose and dosing schedule of ES-3000 in combination with fixed-dose decitabine/cedazuridine (ASTX727). The results indicate a response in 40% of evaluable patients who received ES-3000 as a single agent. The dose-limiting toxicities as per BION modeling allowed the study to dose escalate. A copy of the poster is available at Escend Pharmaceuticals' website About ES-3000 ES-3000 is a small molecule, oral investigational product that reduces leukemic stem cells by β-catenin and Calmodulin protein-dependent kinase II gamma (CamKIIγ). ES-3000 is being developed for the treatment of myeloid malignancies including acute myeloid leukemia (AML), chronic myeloid leukemia (CML), and myelodysplastic syndrome (MDS). About Escend Escend's development strategy is to select drug candidates with established clinical safety that have not yet achieved US marketing approval and develop them for oncology based on new mechanism of action details, where their effects on specific cellular pathways can be leveraged for the development of novel therapeutics. About Australasian Leukaemia and Lymphoma Group's (ALLG) The Australasian Leukaemia and Lymphoma Group (ALLG) is Australia's and New Zealand's only collaborative clinical trial organisation that sponsors local investigator-initiated clinical trials. Established in 1973, the ALLG's membership of over 1,300 blood cancer health professionals at 94 networked sites includes haematologists, clinician researchers, scientists and nurses treating leukaemia, lymphoma, myeloma, myelodysplastic syndromes and other haematological malignancies. The ALLG plans, designs, conducts, monitors and publishes investigator initiated clinical trials to create better treatments and better lives for patients with blood cancers. For further information about this press release, please contact Saira Bates ([email protected]) or visit *Astex Pharmaceuticals study drug SOURCE Escend Pharmaceuticals, Inc.

Press Release Stockholm, Sweden, March 15, 2024 Mendus AB (“Mendus” or the “Company”) has received written declarations of intent whereby the Company’s major shareholders, holding approximately 65.8 percent of shares in the Company, declare their intention to exercise warrants of series TO3 (the “Warrants”) to subscribe for newly issued shares corresponding to their holdings of Warrants during the subscription period 15-29 March 2024 at the subscription price of 0.48 SEK per share. The major shareholders have confirmed that their holdings of Warrants at least equal the number that was allotted to them in connection to their participation in the rights issue in July 2023. All shareholding members of the Company’s Board of Directors and Management team have also declared their intention to exercise all their Warrant holdings. In total, these declarations of intent are expected to result in the exercise of approximately 71.6 percent of the outstanding Warrants. Mendus’ CEO Erik Manting comments: “The commitments by our largest shareholders, together with all the shareholding members of the board and all in the management team, to exercise their warrants which were issued during our latest financing round in July 2023 underscores the progress made by Mendus since. After the positive Phase 2 data presented at the ASH2023 conference in December, we were happy to present the major steps we are taking to expand the clinical development and to scale-up the manufacturing of vididencel together with our partners ALLG and NorthX Biologics at our Business Update event earlier this week. We are also very grateful for the continued support by our shareholders.” The outstanding Warrants were allotted as part of the units that were subscribed for in connection to the preferential rights issue and the directed issue that Mendus carried out in July 2023. If all outstanding Warrants are exercised, the Company will receive approximately SEK 90.6 million in gross proceeds. The declarations of intent are expected to lead to the exercise of approximately 71.6 percent of the outstanding Warrants. The declarations of intent have been made by Van Herk Investments BV, Flerie Invest AB (publ) and Fjärde AP-fonden as well as all shareholding members of the Board of Directors and Management team. The declaration of intent from Van Herk Investments BV is contingent upon them receiving an exemption from the Securities Council (Sv. “Aktiemarknadsnämnden”) to be able to increase their shareholding. In the event that such exemption is not received, Van Herk Investments BV will exercise warrants such that, following the outcome of the exercise period, their percentage ownership will remain unchanged. The declaration of intent from Fjärde AP-fonden to exercise their Warrant holdings is conditional upon their shareholding in the Company not exceeding 9.9 percent. Accordingly, the actual number of Warrants exercised by Van Herk Investments BV and Fjärde AP-fonden will depend on the aforementioned conditions. FOR MORE INFORMATION, PLEASE CONTACT: Erik MantingChief Executive OfficerE-mail: ir@mendus.com ABOUT MENDUS AB (PUBL)Mendus is dedicated to changing the course of cancer treatment by addressing tumor recurrence and improving survival outcomes for cancer patients, while preserving quality of life. We are leveraging our unparalleled expertise in allogeneic dendritic cell biology to develop an advanced clinical pipeline of novel, off-the-shelf, cell-based immunotherapies which combine clinical efficacy with a benign safety profile. Based in Sweden and The Netherlands, Mendus is publicly traded on the Nasdaq Stockholm under the ticker IMMU.ST. https://www.mendus.com/ Attachment 240315 Mendus - Warrants Commitment ENG

Press Release Stockholm, Sweden, March 12, 2024 ADVANCE II Phase 2 trial data provide basis for late-stage development of lead product vididencel in acute myeloid leukemiaRegistration trial preparations are ongoing, following positive initial FDA feedback on main questions related to late-stage clinical development and large-scale manufacturingManufacturing alliance with NorthX Biologics on track, with production facility installed and tech transfer process for large-scale GMP manufacturing of vididencel initiatedCollaboration with ALLG to study vididencel in combination with oral azacitidine progressing according to earlier guidance, with AMLM22-CADENCE trial expected to start patient enrolment in April 2024Live Business Update event to be held today, March 12, 15.00-17.00 CET Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, announces a business update and outlook for the development of its lead product vididencel in acute myeloid leukemia (AML) during a live investor event to be held today, March 12, 15.00-17.00 CET. Vididencel is developed as an AML maintenance therapy, addressing the high medical need to prolong disease-free and overall survival following initial chemotherapy. Mendus presented positive survival data from the ADVANCE II Phase 2 clinical trial at the annual meeting of the American Society for Hematology (ASH) in December 2023, demonstrating durable clinical remissions associated with broad immune responses following vididencel treatment in the majority of patients. Mendus has entered into a collaboration with the Australian Leukemia and Lymphoma Group (ALLG), a world-leading group in clinical research for blood-borne tumors, to expand the clinical development of vididencel. The collaboration will support a multicenter, randomized controlled trial of vididencel in combination with oral azacitidine, currently the only approved AML maintenance drug. The collaboration is on track and recruitment for the AMLM22-CADENCE trial is expected to commence in April 2024. Mendus is preparing for a global registration strategy of vididencel as a novel AML maintenance treatment. Mendus received positive feedback from the US FDA regarding the main topics related to late-stage clinical development of vididencel in AML, including the proposed steps towards large-scale manufacturing. Mendus has secured a manufacturing alliance with NorthX Biologics, a specialized Nordic cell and gene therapy custom manufacturing organization. The alliance has successfully completed the installation of the vididencel production facility and has started the implementation phase of the technology transfer from Mendus to NorthX. “The positive ADVANCE II data provide us with a unique opportunity to develop vididencel in AML,” said Erik Manting, CEO of Mendus. “Initial big steps have been taken in the collaborations with ALLG and NorthX Biologics and we are encouraged by the positive FDA feedback on the main topics related to late-stage clinical development and large-scale manufacturing of vididencel. The potential large impact of vididencel as a novel maintenance treatment option for AML patients is what drives us in preparing for a global registration strategy.” In-person and live-streamed business update event in Stockholm on March 12, 15.00-17.00 CET Mendus will host a business update event later today to present the next steps in the development of vididencel as a promising new maintenance treatment option for AML patients, together with its strategic partners ALLG and NorthX Biologics. Venue: Inderes Event Studio (Västra Trädgårdsgatan 19, Stockholm) Date and time: March 12 at 15.00–17.00 CET, registration is open from 14.30 Please register to attend via email to ir@mendus.com Those unable to attend in person can listen to the presentation webcast: https://ir.financialhearings.com/mendus-business-update-march-2024 For more information, please contact:Erik MantingChief Executive OfficerE-mail: ir@mendus.com About Mendus AB (publ) Mendus is dedicated to changing the course of cancer treatment by addressing tumor recurrence and improving survival outcomes for cancer patients, while preserving quality of life. We are leveraging our unparalleled expertise in allogeneic dendritic cell biology to develop an advanced clinical pipeline of novel, off-the-shelf, cell-based immunotherapies which combine clinical efficacy with a benign safety profile. Based in Sweden and The Netherlands, Mendus is publicly traded on the Nasdaq Stockholm under the ticker IMMU.ST. https://www.mendus.com/ Attachment 240312 Mendus Business Update ENG